PL3104838T3 - Terapeutyczne nanocząstki zawierające środki terapeutyczne oraz ich sposoby wytwarzania i zastosowanie - Google Patents

Terapeutyczne nanocząstki zawierające środki terapeutyczne oraz ich sposoby wytwarzania i zastosowanie

Info

Publication number
PL3104838T3
PL3104838T3 PL15707019T PL15707019T PL3104838T3 PL 3104838 T3 PL3104838 T3 PL 3104838T3 PL 15707019 T PL15707019 T PL 15707019T PL 15707019 T PL15707019 T PL 15707019T PL 3104838 T3 PL3104838 T3 PL 3104838T3
Authority
PL
Poland
Prior art keywords
therapeutic
making
methods
same
nanoparticles
Prior art date
Application number
PL15707019T
Other languages
English (en)
Inventor
Maria Figueiredo
Erick PEEKE
David Dewitt
Christina Van Geen Hoven
Greg Troiano
James Wright
Young-Ho Song
Hong Wang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3104838T3 publication Critical patent/PL3104838T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
PL15707019T 2014-02-13 2015-02-13 Terapeutyczne nanocząstki zawierające środki terapeutyczne oraz ich sposoby wytwarzania i zastosowanie PL3104838T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939363P 2014-02-13 2014-02-13
PCT/US2015/015887 WO2015123562A1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP15707019.4A EP3104838B1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (1)

Publication Number Publication Date
PL3104838T3 true PL3104838T3 (pl) 2020-07-13

Family

ID=52595474

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15707019T PL3104838T3 (pl) 2014-02-13 2015-02-13 Terapeutyczne nanocząstki zawierające środki terapeutyczne oraz ich sposoby wytwarzania i zastosowanie

Country Status (11)

Country Link
US (2) US10080723B2 (pl)
EP (1) EP3104838B1 (pl)
JP (1) JP6573895B2 (pl)
CA (1) CA2939261C (pl)
DK (1) DK3104838T3 (pl)
ES (1) ES2770733T3 (pl)
HU (1) HUE047934T2 (pl)
PL (1) PL3104838T3 (pl)
PT (1) PT3104838T (pl)
SI (1) SI3104838T1 (pl)
WO (1) WO2015123562A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3104838T (pt) 2014-02-13 2020-02-14 Pfizer Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
EP4299058A3 (en) 2014-06-24 2024-03-27 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US20170049709A1 (en) 2015-08-21 2017-02-23 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
JP2019509299A (ja) * 2016-03-22 2019-04-04 ファイザー・インク 治療用ナノ粒子を調製する方法
CA3060306A1 (en) 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US12357582B2 (en) 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
EP3784705A4 (en) * 2018-04-23 2022-03-02 Graybug Vision, Inc. IMPROVED CONTINUOUS PRODUCTION OF MICROPARTICLES
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2024108094A1 (en) * 2022-11-18 2024-05-23 Haima Therapeutics, Llc Lyophilization buffers for peptide-decorated liposomes
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869884B2 (en) * 2002-08-22 2005-03-22 Chartered Semiconductor Manufacturing Ltd. Process to reduce substrate effects by forming channels under inductor devices and around analog blocks
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
AU2013315125B2 (en) 2012-09-17 2018-07-26 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP2895156B1 (en) 2012-09-17 2019-05-08 Pfizer Inc. Process for preparing therapeutic nanoparticles
PE20160930A1 (es) * 2013-09-16 2016-09-03 Astrazeneca Ab Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
PT3104838T (pt) 2014-02-13 2020-02-14 Pfizer Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
ES2834927T3 (es) * 2014-03-14 2021-06-21 Pfizer Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas

Also Published As

Publication number Publication date
DK3104838T3 (da) 2020-02-24
JP6573895B2 (ja) 2019-09-11
US20190111004A1 (en) 2019-04-18
US10583092B2 (en) 2020-03-10
ES2770733T3 (es) 2020-07-02
JP2017505800A (ja) 2017-02-23
EP3104838B1 (en) 2020-01-01
HUE047934T2 (hu) 2020-05-28
WO2015123562A1 (en) 2015-08-20
US20170042828A1 (en) 2017-02-16
US10080723B2 (en) 2018-09-25
CA2939261A1 (en) 2015-08-20
SI3104838T1 (sl) 2020-04-30
PT3104838T (pt) 2020-02-14
EP3104838A1 (en) 2016-12-21
CA2939261C (en) 2023-03-28

Similar Documents

Publication Publication Date Title
IL257318A (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
ZA201606646B (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL250415B (en) Antibodies against pd-l and methods of using them
GB2554283B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
SG10202002593SA (en) Activated bifidobacteria and methods of use thereof
PT3104838T (pt) Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
GB201502084D0 (en) Catheter devices and related methods
SG10201406612RA (en) Mask structures and methods of manufacturing
GB201418350D0 (en) Dispenser and methods of use thereof
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
GB201404470D0 (en) Therapeutic methods and materials
AP2016009088A0 (en) Therapeutic polymeric nanoparticles and methods of making and using same
IL253234A0 (en) Methods for transdifferentiation and methods to use them
IL259047A (en) Nanoparticles containing a therapeutic substance, a process for their preparation and uses
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
ZA201606450B (en) Compounds and their methods of use
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
GB201418809D0 (en) Therapeutic agents and uses thereof
IL252508A0 (en) Oxidized lipids and their uses
GB2588276B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
GB201417248D0 (en) Compostion and methods of treatment
GB201408171D0 (en) Formulation and method of manufacture